Stem Cell Therapy for Neurological and Cardiovascular Diseases is under clinical development by Saneron CCEL Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Stem Cell Therapy for Neurological and Cardiovascular Diseases’s likelihood of approval (LoA) and phase transition for Acute Ischemic Stroke took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Stem Cell Therapy for Neurological and Cardiovascular Diseases Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Stem Cell Therapy for Neurological and Cardiovascular Diseases overview

Stem cell therapy (HUCBC therapy) is under development for the treatment of acute ischemic stroke. The cell therapy is developed based on Human Umbilical-CORD-CELL stem cell technology platform. The therapeutic candidate was also under development for the treatment of myocardial infarction, spinal cord injury, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and cognitive disorders.

Saneron CCEL Therapeutics overview

Saneron CCEL Therapeutics (Saneron) is a biotechnology company that conducts research on neurological and cardiac cell therapies for early intervention and treatment of deadly diseases. The company’s research and development programs include SERT-CELL program and U-CORD-CELL program. Its U-CORD-CELL program is a stem cell technology platform that explores dual approaches to the development of medical treatments for replacing damaged cells and tissues. Saneron’s SERT-CELL program explores the distinctive potential of sertoli cells, which inhibit immune reactions to foreign tissues. The company also provides stem cells and other cell types for cellular therapies. Its programs are used to research for neurological cell therapy. Saneron is headquartered in Tampa, Florida, the US.

Quick View Stem Cell Therapy for Neurological and Cardiovascular Diseases LOA Data

Report Segments
  • Innovator
Drug Name
  • Stem Cell Therapy for Neurological and Cardiovascular Diseases
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.